Legal Hold and Records Retention Schedules Preservation Guidelines
All data, including recorded meetings, that have content subject to a legal hold or a record retention schedule must be preserved and/or retained.
Data must be retained if it is subject to a legal hold notice or subject to a records retention schedule. For more information concerning records retention, refer to the Company records retention schedules. If you have any questions regarding legal hold, please email firstname.lastname@example.org for assistance.
Organon Meetings may be recorded. Documents and other materials exchanged or viewed during the session may also recorded. BY JOINING THIS SESSION, YOU AUTOMATICALLY CONSENT TO SUCH RECORDINGS. If you do not consent to being recorded, discuss your concerns with the host or do not join the session. Any such recordings may be subject to discovery in litigation.
Company operations in other jurisdictions (ex-US) should review preservation requirements with LOCAL Counsel, Privacy, and/or Records Management teams to ensure that there are NO conflicting LOCAL privacy, regulatory, and /or Legal requirements.
Information lifecycle management is the responsibility of the information owner (creator, author, and/or custodian). All data formats, including recorded meetings, that have content under legal hold, or are responsive to a record retention schedule, regulatory, privacy, and/or business continuity/Intellectual property requirement must be preserved/ retained in a Company approved repository.
This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.